

BMI CHART

Hiranandani Fortis Hospital

Mini Seashore Road, Sector 10 - A, Vashi, Navi Mumbai - 400 703.

Tel.: +91-22-3919 9222 Fax: +91-22-3919 9220/21 Email: vashi@vashihospital.co

Date: 11 1021 2

Signature

				¥		
Name: Mrs.	Alska Cl	achon	Age: 38_yr	s	Sex: M / F	
BP: 116/70	Height (cms):	GICM V	Veight(kgs):66	ay	вмі: <a>	s ⁹
ē.	e V)		27.00 A

kgs	45.5	47.7	50.50	52.3	54.5	56.8			63.6	65 9	68.2		72.7	165 75.0	170 77.3	175 79.5	180	185	190	195	200	205	210	25.012
HEIGHT in/cm		7	derwe				Hea			00.5	T	71	rweig		11.3	79.5	81.8 Obe		86.4	88.6		93.2 reme	2000	ž.
5'0" - 152.4	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35		07	- 00				-
5'1" - 154.9	18		20			_		0					30	31	32	33		36	37	38	39	40	41	42
5'2" - 157.4	18		20	1				ti .					29	30	31	32	34	35	36	36	37	38	39	40
5'3" - 160.0	17	-	19			1	4	1,000				<u></u>	28	29	30	31	32	32	34	35	36	37	38	39
5'4" - 162.5	17	18				6			24		25		27	28	29	30	31	31	32	33	35	36	37	38
5'5" - 165.1	16	17	18	-		_			23	-	25	1	-			29	30	30	31	32	33	34	35	35
5'6" - 167.6	16	17	17				1		22			25	11				29	29	30	31	32	33	34	34
5'7" - 170.1	15	16	17	18	-				22			24					28	29	29	30	31	32	33	33
5'8" - 172.7	15	16	16	17	18	1		1	21					25	51		27	28	28	29	30	31	32	32
5'9" - 176.2	14-	15	16	17	17	18	19	20	20	_			1	24			26	27	28	28	29	30	31	31
5'10" - 177.8	14	15	15	16	17	18	18	19	20	MITTER STATE	-	Acres	1	23	The same		25	26	27	28	28	29	30	30
5'11" - 180.3	14	14	15	16	16	17	18	18	19		-			1		24		1000	26	27	28	28	29	30
5'0" - 182.8	13	14	14	15	16	17	17	18	19	_	-	40000		-	1	23		-		26		27	28	29
6'1" - 185.4	13	13	14	15	15	16	17	17	18	-	19	Contract of the Contract of th	Section .	-		23				25			27	28
6'2" - 187.9	12	13	14	14	15	16	16	17	18	18	19		-	21	General Person	22			-		25	-	27	27
6'3" - 190.5	12	13	13	14	15	15	16	16	17	18	18	19	20	20	-	21			-		Partie Block		26	26
6'4" - 193.0	12	12	13	14	14	15	15	16	17	17	18	18		-	·	-	-		23					26

Doctors Notes:	E # **		5. Ā	ě	
* *		. xe	Fig.		128
* * *	2 2		522	- 9	
8	0.00		-	2	0Î
	K		41	6	
ev s		as as			8
6 ×			20 29	5 ° 5	+

Hiranandani Healthcare Pvt. Ltd. Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703 Board Line: 022 - 39199222 | Fax: 022 - 39199220

Emergency: 022 - 39199100 | Ambulance: 1255 For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | CIN : U85100MH2005PTC154823 GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D

UHID	12288318	Date	11/02/2023		
Name	Mrs.Alka Chouhan	Sex	Female	Age	38
OPD	Pap Smear	Healtl	h Check U	p	J

Drug allergy: Sys illness:

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D

UHID	12288318	Date	11/02/20		
Name	Mrs.Alka Chouhan	Sex	Female	Age	38
OPD	Opthal 14	Healt	h Check U	p	

Drug allergy: Not know.

Sys illness: Not know. Pa Phuel-050x 100 6/6

G Phuel-0.78x 60'6/9P

S Phuel-0.78x 60'6/9P

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D

UHID	12288318	Date 11/02/2023			
Name	Mrs.Alka Chouhan	Sex	Female	Age	38
OPD	Dental 12	Healt	h Check U	p	

Drug allergy: Sys illness:

Adv Old prophylexis

Dighe keke



PATIENT NAME: MRS.ALKA CHOUHAN





PATIENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO: 0022WB002187 AGE: 38 Years

SEX: Female

REFERRING DOCTOR:

ABHA NO :

11/02/2023 15:09:22

DRAWN: 11/02/2023 13:34:00

RECEIVED: 11/02/2023 13:41:59

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Test Report Status

Final

Results

Biological Reference Interval

Units

BIOCHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

84

70 - 139

mg/dL

METHOD: HEXOKINASE

Comments

NOTE: POST PRANDIAL PLASMA GLUCOSE VALUES. TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin CLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and Plasma fasting glucose level may be seen due to effect of Oral Hypoglycaemics and

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr.Akta Dubey

Counsultant Pathologist

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -







Scan to View Report





PATIENT NAME: MRS.ALKA CHOUHAN





PATIENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO: 0022WB002055 AGE: 38 Years

SEX: Female

ABHA NO:

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

11/02/2023 15:40:32

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Test Report Status Final Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3

111.20

Non-Pregnant Women

ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester: 105.0 - 230.0

2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

T4

7.26

Non-Pregnant Women

µg/dL

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

TSH (ULTRASENSITIVE)

1.280

0.270 - 4.200

µIU/mL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY Interpretation(s)

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam

Consultant Pathologist

SRL Ltd BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR

NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,


CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report





PATIENT NAME: MRS.ALKA CHOUHAN

FH.12288318

CLIENT PATIENT ID: UID:12288318

ABHA NO:

REPORTED: 11/02/2023 15:23:36

PATIENT ID:

ACCESSION NO: 0022WB002055 AGE: 38 Years

SEX: Female

DRAWN: 11/02/2023 09:57:00 CLIENT NAME : FORTIS VASHI-CHC -SPLZD

RECEIVED: 11/02/2023 09:57:43

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444

Test Report Status <u>Final</u>	Results	Biological Reference Inter	val Units
KIDNEY PANEL - 1		9	
BLOOD UREA NITROGEN (BUN), SERUM			ma/dl
BLOOD UREA NITROGEN	9	6 - 20	mg/dL
METHOD: UREASE - UV			
CREATININE EGFR- EPI			
CREATININE	0.75	0.60 - 1.10	mg/dL
METHOD: ALKALINE PICRATE KINETIC JAFFES			worr.
AGE	38		years
GLOMERULAR FILTRATION RATE (FEMALE)	104.44		mL/min/1.
BUN/CREAT RATIO			
BUN/CREAT RATIO	12.00	5.00 - 15.00	
METHOD: CALCULATED PARAMETER			
URIC ACID, SERUM			27 1040
URIC ACID	4.3	2.6 - 6.0	mg/dL
METHOD: URICASE UV			
TOTAL PROTEIN, SERUM			Servine Sea
TOTAL PROTEIN	7.1	6.4 - 8.2	g/dL
METHOD: BIURET			
ALBUMIN, SERUM			
ALBUMIN	3.7	3.4 - 5.0	g/dL
METHOD: BCP DYE BINDING			
GLOBULIN			7000
GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER	整		
ELECTROLYTES (NA/K/CL), SERUM			*. ******* n
SODIUM, SERUM	. 138	136 - 145	mmol/L
METHOD: ISE INDIRECT		the state of the late	ercenter service
POTASSIUM, SERUM	3.90	3.50 - 5.10	mmol/L
METHOD: ISE INDIRECT		700 X00	mmal/I
CHLORIDE, SERUM	102	98 - 107	mmol/L
METHOD: ISE INDIRECT			
Interpretation(s)			

PHYSICAL EXAMINATION, URINE


COLOR

PALE YELLOW

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report





PATIENT NAME: MRS.ALKA CHOUHAN





PATTENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO: 0022WB002055 AGE: 38 Years

SEX: Female

ABHA NO:

11/02/2023 15:23:36

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Results

Biological Reference Interval

Test Report Status

Units

METHOD: PHYSICAL

APPEARANCE

SLIGHTLY HAZY

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

6.5

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD

1.003 - 1.035

SPECIFIC GRAVITY

 ≤ 1.005

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION) NOT DETECTED NOT DETECTED

PROTEIN

GLUCOSE

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

KETONES

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

DETECTED (++)

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

NOT DETECTED

NOT DETECTED

BILIRUBIN METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

UROBILINOGEN

NORMAL

NORMAL

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NITRITE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

8 - 10

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S)

EPITHELIAL CELLS

3-5

0-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

8-10

0-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

CASTS

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED

CRYSTALS

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

BACTERIA

DETECTED (FEW)

METHOD: MICROSCOPIC EXAMINATION

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10, NAVI MUMBAI, 400703


MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report





PATIENT NAME: MRS.ALKA CHOUHAN





PATIENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO:

0022WB002055 AGE: 38 Years

SEX: Female

ABHA NO:

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

METHOD: MICROSCOPIC EXAMINATION

Results

Biological Reference Interval

Test Report Status

YEAST

NOT DETECTED

NOT DETECTED

REMARKS

URINARY MICROSCOPIC EXAMINATION DONE ON URINARY

CENTRIFUGED SEDIMENT.

Interpretation(s)

Interpretation(s)
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.

Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test.

Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range.

A GFR below 60 may mean kidney disease.

A GFR below 60 may mean kidney disease.

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Rer Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Rer Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Rer Estimated GFR (eGFR) is the preferred method for petients alone.

Disease (MDRD) Study equation, but uses a 2-slope spline to model the relationship between estimal The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimal GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimal GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimal GFR and Study equation, but uses a 2-slope spline to model the relationship between estimal GFR and Study equation, but uses a 2-slope spline to model the relationship between estimal GFR and Study equation, but uses a 2-slope spline to model the relationship between estimal the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimal the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimal the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimal the

The CKD-EPI creatinine equation has not been variable in Gindren & Will only be reported for patients — 10 years of age, for pediatric and children's, Schwarz Pediatric Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasm

made up of albumin and globulin

Lower-than-normal levels may be due to: Agammagiobulinemia, bleeding (hemormage), burns, Glomerulonephilius, Liver disease, Malausorption, Ma

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report





LABORATORY REPORT PATIENT NAME: MRS.ALKA CHOUHAN





PATIENT ID : FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO: 0022WB002055 AGE: 38 Years

SEX: Female

ABHA NO:

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

T+	Report	Chatue	Final	
Test	Kebuit	Status	ГШаі	

Results

Biological Reference Interval


		CRC		
	HAEMATOLOGY ·	- CBC		
CBC-5, EDTA WHOLE BLOOD				
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	12.6		12.0 - 15.0	g/dL
METHOD: SPECTROPHOTOMETRY				
RED BLOOD CELL (RBC) COUNT	5.85	High	3.8 - 4.8	mil/µL
METHOD: ELECTRICAL IMPEDANCE				1881 1812
WHITE BLOOD CELL (WBC) COUNT	6.36		4.0 - 10.0	thou/µL
METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CYTOMETRY			
PLATELET COUNT	222		150 - 410	thou/µL
METHOD: ELECTRICAL IMPEDANCE				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	39.3		36 - 46	%
METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME (MCV)	67.2	Low	83 - 101	fL
METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	21.6	Low	27.0 - 32.0	pg
METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN	32.1		31.5 - 34.5	g/dL
CONCENTRATION(MCHC)				
METHOD : CALCULATED PARAMETER	15.1	High	11.6 - 14.0	%
RED CELL DISTRIBUTION WIDTH (RDW)	13.1		11.014.0	,,,
METHOD : CALCULATED PARAMETER	11.5		*	
MENTZER INDEX	12,0		6.8 - 10.9	fL
MEAN PLATELET VOLUME (MPV)	9.3		0.0 - 10.9	Ů a
METHOD: CALCULATED PARAMETER				
WBC DIFFERENTIAL COUNT			40. 00	0/
NEUTROPHILS	51		40 - 80	%
METHOD: FLOWCYTOMETRY				Ž.
LYMPHOCYTES	34		20 - 40	%
METHOD: FLOWCYTOMETRY			- 17W	
MONOCYTES	10		2 - 10	%
METHOD: FLOWCYTOMETRY	No.			**
EOSINOPHILS	05		1 - 6	%
METHOD: FLOWCYTOMETRY				

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -







Scan to View Report





PATIENT NAME: MRS.ALKA CHOUHAN

CLIENT PATIENT ID: UID:12288318

PATIENT ID:

FH.12288318

ACCESSION NO:

DRAWN: 11/02/2023 09:57:00

0022WB002055 AGE: 38 Years RECEIVED: 11/02/2023 09:57:43

SEX: Female

ABHA NO: REPORTED:

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

BILLNO-1501230PCR008444							
Test Report Status <u>Final</u>	Results	Biological Reference	Interval				
Test Report Status Thirds							
Married ar	00	0 - 2	%				
BASOPHILS	2.2						
METHOD : FLOWCYTOMETRY	3.24	2.0 - 7.0	thou/µL				
ABSOLUTE NEUTROPHIL COUNT	J. L						
METHOD : CALCULATED PARAMETER	2.16	1.0 - 3.0	thou/µL				
ABSOLUTE LYMPHOCYTE COUNT	2.10		¥1				
METHOD: CALCULATED PARAMETER	0.64	0.2 - 1.0	thou/µL				
ABSOLUTE MONOCYTE COUNT	0.04						
METHOD: CALCULATED PARAMETER	0.32	0.02 - 0.50	thou/µL				
ABSOLUTE EOSINOPHIL COUNT	0.32	3.3 2					
METHOD: CALCULATED PARAMETER		Low 0.02 - 0.10	thou/µL				
ABSOLUTE BASOPHIL COUNT	0	0.02					
METHOD: CALCULATED PARAMETER	20 P						
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.5						
METHOD: CALCULATED PARAMETER							
MORPHOLOGY	1 ×27=10 × 000 A 4 × 2	WILD ANIC	OCYTOSIS				
RBC	NORMOCHRO	MIC, MICROCYTOSIS(+), MILD ANIS	00110313				
METHOD: MICROSCOPIC EXAMINATION	SERVICES IN SERVICES - COMMISSION -						
WBC	NORMAL MOR	PHOLOGY					
METHOD: MICROSCOPIC EXAMINATION							
PLATELETS	ADEQUATE						
METHOD: MICROSCOPIC EXAMINATION							

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>1)
from Beta thalassaemia trait

from Beta thalassaemia trait
(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive was patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and for 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 10 This ratio element is a calculated parameter and out of NABL scope.

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R

19

0 - 20

mm at 1 l

METHOD: WESTERGREN METHOD

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report





RY REPORT NAME : MRS.ALKA CHOUHAN

Fortis



PATIENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO:

0022WB002055 AGE:

38 Years

SEX: Female

ABHA NO:

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED :

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Test Report Status

Final

Results

Biological Reference Interval

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that the properties of the type of type of type of the type of type o are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Increase in: Inections, Vasculates, Inflaminatory artiflats, Renardisease, Alternal, Indignated and plasma can dysocial activities. Particularly and plasma can dysocial activities and plasma can dysocial activities. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm/hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference fc the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE O

POSITIVE

METHOD: TUBE AGGLUTINATION

RH TYPE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

BIOCHEMISTRY

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL

1.01

High 0.2 - 1.0

mg/dL

METHOD: JENDRASSIK AND GROFF BILIRUBIN, DIRECT

0.19

0.0 - 0.2

mg/dL

METHOD: JENDRASSIK AND GROFF

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report





LABORATORY REPORT PATIENT NAME : MRS.ALKA CHOUHAN





PATIENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO: 0022WB002055 AGE: 38 Years

SEX: Female

ABHA NO:

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Test Report Status Final		Results	Biological Reference Inter	Biological Reference Interval			
#2 (20 HOOLE)							
BILIRUBIN, INDIRECT		0.82	0.1 - 1.0	mg/dL			
METHOD: CALCULATED PARAMETER			64.02	g/dL			
TOTAL PROTEIN		7.1	6.4 - 8.2	g/dL			
METHOD : BIURET		2.7	3.4 - 5.0	g/dL			
ALBUMIN		3.7	3.4 - 5.0	9, 42			
METHOD : BCP DYE BINDING		3.4	2.0 - 4.1	g/dL			
GLOBULIN		3.4	2.0 4.1	31			
METHOD : CALCULATED PARAMETER		1.1	1.0 - 2.1	RATIO			
ALBUMIN/GLOBULIN RATIO	9	1.1	· · · · · · · · · · · · · · · · · · ·				
METHOD: CALCULATED PARAMETER ASPARTATE AMINOTRANSFER	ASE (AST/SGOT)	. 20	15 - 37	U/L			
METHOD: UV WITH P5P	ASE (ASI/SCO!)						
ALANINE AMINOTRANSFERASI	E (ALT/SGPT)	18	< 34.0	U/L			
METHOD: UV WITH P5P	- (,,						
ALKALINE PHOSPHATASE		65	30 - 120	U/L			
METHOD: PNPP-ANP							
GAMMA GLUTAMYL TRANSFER	ASE (GGT)	21	5 - 55	U/L			
METHOD: GAMMA GLUTAMYLCARBO)	Y 4NITROANILIDE			270744			
LACTATE DEHYDROGENASE		154	100 - 190	U/L			
METHOD: LACTATE -PYRUVATE							
AL WAR OF EACTING FILLION	IDE DI ASMA	*					
GLUCOSE FASTING, FLUOR		85	74 - 99	mg/dL			
FBS (FASTING BLOOD SUGAR	()	63	7:3 033	5/			
METHOD: HEXOKINASE							
GLYCOSYLATED HEMOGLO	BIN(HBA1C), EDT/	A					
WHOLE BLOOD HBA1C		5.6	Non-diabetic: < 5.7	%			
HBAIC			Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)				
METHOD: HB VARIANT (HPLC)			· · · · · · · · · · · · · · · · · · ·				
ESTIMATED AVERAGE GLUCO METHOD: CALCULATED PARAMETER		114.0	< 116.0	mg/dL			

SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel: 022-39199222,022-49723322,
CIN - U74899PR 195PI C045956

CIN - U74899PB1995PLC045956







Scan to View Report





LABORATORY REPORT PATIENT NAME: MRS.ALKA CHOUHAN

Fortis



PATTENT ID :

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO:

0022WB002055 AGE:

38 Years

SFX: Female

ABHA NO :

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Results

Biological Reference Interval

Test Report Status

Final

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give
yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg
obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated
(indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when
there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirub
may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that
attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the literature of the properties of the body.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood, is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALR is a protein found in almost all hoods tiesues. Tiesues with blober amounts of ALR is a protein found in almost all hoods are seen in Bilizary extension.

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction. Steoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget'''s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson'''s disease, GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, bilic system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum, Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom''s disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephi syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes abou half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs- Insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. The glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1.Evaluating the long-term control of blood glucose concentrations in additional forms and a state of the long-term control of blood glucose (prediabetes).

3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to:

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbillrubinemia, chronic alcoholism, chronic ingestion of salicylates & opia addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

recommended for detecting a hemoglobinopathy

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10. NAVI MUMBAI, 400703 MAHARASHTRA, INDIA


Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report





LABORATORY REPORT PATIENT NAME : MRS.ALKA CHOUHAN





PATIENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO: 0022WB002055 AGE: 38 Years

SEX: Female

ABHA NO :

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Test Report Status

Final

Results

Biological Reference Interval

BIOCHEMISTRY - LIPID

TOTO	DROFT	I F	SERIII	v1

CHOLESTEROL, TOTAL

125

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES

48

< 150 Normal

mg/dL

150 - 199 Borderline High 200 - 499 High

>/=500 Very High

METHOD: ENZYMATIC ASSAY

METHOD: DIRECT MEASURE - PEG

LDL CHOLESTEROL, DIRECT

HDL CHOLESTEROL

51

73

< 40 Low >/=60 High mg/dL

< 100 Optimal

mg/dL

100 - 129 Near or above optimal

130 - 159 Borderline High

160 - 189 High

>/= 190 Very High

METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

NON HDL CHOLESTEROL

74

Desirable: Less than 130 Above Desirable: 130 - 159

Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

METHOD: CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN

9.6

</= 30.0

mg/dL

mg/dL

METHOD : CALCULATED PARAMETER

CHOL/HDL RATIO

2.5

Low 3.3 - 4.4 Low Risk

4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk

> 11.0 High Risk

METHOD: CALCULATED PARAMETER

LDL/HDL RATIO

1.4

0.5 - 3.0 Desirable/Low Risk

3.1 - 6.0 Borderline/Moderate Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER

Interpretation(s)

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report





LABORATORY REPORT ATTENT NAME: MRS.ALKA CHOUHAN





PATIENT ID:

FH.12288318

CLIENT PATIENT ID: UID:12288318

ACCESSION NO:

0022WB002055 AGE: 38 Years

SEX: Female

ABHA NO:

DRAWN: 11/02/2023 09:57:00

RECEIVED: 11/02/2023 09:57:43

REPORTED:

11/02/2023 15:23:36

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:12288318 REQNO-1370821

CORP-OPD

BILLNO-1501230PCR008444 BILLNO-1501230PCR008444

Test Report Status

Final

Results

Biological Reference Interval

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr.Akta Dubey

Counsultant Pathologist

Dr. Rekha Nair, MD

Microbiologist

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report



12288318 38 Years	ALKA CHOUHAN Female	2/11/2023 1:56:56 PM	:56:56 PM
Rate 52	Sinus rhythm	normal P axis, V-rate 50-99	sity bratication
PR 145 QRSD 90 QT 411 QTC 383	£		Correlate Chinish
AXIS P 51 ORS 58	0	- OTHERWISE NORMAL ECG -	
Lead;	21 Standard Placement	Unconfirmed Diagnosis	
H	avr	δά	
JI.	J.A.	SA SA	
3			
II.	3/16	9A	
11 3			
Device:	Speed: 25 mm/sec Limb: 10 :	10 mm/mV Chest: 10.0 mm/mV F 5	50~ 0.50-100 Hz ₩ 100B CL.

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 11/Feb/2023

Name: Mrs. Alka Chouhan

Age | Sex: 38 YEAR(S) | Female Order Station : FO-OPD

Bed Name:

UHID | Episode No : 12288318 | 8662/23/1501

Order No | Order Date: 1501/PN/OP/2302/17755 | 11-Feb-2023

Admitted On | Reporting Date: 11-Feb-2023 12:57:34 Order Doctor Name: Dr.SELF.

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

DR. YOGINI SHAH

Helsi

DMRD., DNB. (Radiologist)

lini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

oard Line: 022 - 39199222 | Fax: 022 - 39133220

Imergency: 022 - 39199100 (Ambulance: 1255 For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





Date: 11/Feb/2023 DEPARTMENT OF RADIOLOGY UHID | Episode No: 12288318 | 8662/23/1501

Order No | Order Date: 1501/PN/OP/2302/17755 | 11-Feb-2023 Name: Mrs. Alka Chouhan

Admitted On | Reporting Date: 11-Feb-2023 13:27:57 Order Doctor Name : Dr.SELF . Age | Sex: 38 YEAR(S) | Female

Order Station: FO-OPD Bed Name:

USG-WHOLE ABDOMEN

LIVER is normal in size and echogenicity. No IHBR dilatation. No focal lesion is seen in liver.

GALL BLADDER is physiologically distended. Gall bladder reveals normal wall thickness. No Portal vein appears normal in caliber. evidence of calculi in gall bladder. No evidence of pericholecystic collection. CBD appears normal in caliber.

SPLEEN is normal in size and echogenicity. BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 10.2 x 3.1 cm.

PANCREAS is normal in size and morphology. No evidence of peripancreatic collection. Left kidney measures 9.8 x 3.5 cm.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

UTERUS is normal in size, measuring 8.8 x 3.7 x 5.1 cm. Endometrium measures 4 mm in thickness.

Both ovaries are normal. Right ovary measures 3.0 x 1.5 cm.

Left ovary measures 2.3 x 1.1 cm.

No evidence of ascites.

IMPRESSION:

No significant abnormality is detected.

DR. YOGINI SHAH DMRD., DNB. (Radiologist) miranangani meaithcare PVI. Ltg.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 13/Feb/2023

Name: Mrs. Alka Chouhan

Age | Sex: 38 YEAR(\$) | Female

Order Station: FO-OPD Bed Name: UHID | Episode No: 12288318 | 8662/23/1501

Order No | Order Date: 1501/PN/OP/2302/17755 | 11-Feb-2023

Admitted On | Reporting Date: 13-Feb-2023 10:36:21

Order Doctor Name: Dr.SELF.

MAMMOGRAM - BOTH BREAST

Findings:

Bilateral film screen mammography was performed in cranio-caudal and medio-lateral oblique views.

Both breasts are heterogeneously dense which may obscure small masses.

No evidence of clusters of microcalcifications, nipple retraction, skin thickening or abnormal vascularity is seen in either breast.

No evidence of axillary lymphadenopathy.

IMPRESSION:

 Both breasts are heterogeneously dense which may obscure small masses. (BI-RADS category 0). Advice sonography of breast.

DR. YOGINI SHAH

DMRD., DNB. (Radiologist)